| Bioactivity | ITF 3756 is a potent and selective HDAC6 inhibitor. ITF 3756 reduces in vitro the expression of PD-L1 on human monocytes and on CD8 T cells, and shows anti-tumor activity[1]. | ||||||||||||
| Name | ITF 3756 | ||||||||||||
| CAS | 2247608-27-9 | ||||||||||||
| Formula | C13H11N5O2S | ||||||||||||
| Molar Mass | 301.32 | ||||||||||||
| Appearance | 固体 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Gianluca Fossati, et al. Abstract 1358: The selective HDAC6 inhibitor ITF3756 stimulates an antitumor immune response and leads to tumor regression in combination with anti CTLA-4 antibody in a colon carcinoma murine model. Cancer Res (2022) 82 (12_Supplement): 1358. |
ITF 3756
CAS: 2247608-27-9 F: C13H11N5O2S W: 301.32
ITF 3756 is a potent and selective HDAC6 inhibitor. ITF 3756 reduces in vitro the expression of PD-L1 on human monocytes
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.